What did CJC-1295 research find in people?
You can start with growth hormone and IGF-1, the liver-made hormone tied to growth and repair. Then compare those results with animal work and safety gaps.
How does the drug start hormone release?
CJC-1295 copies one message your body uses and reaches a receiving place on growth-gland cells. The cell passes that message inside and releases hormone stored in the gland [2]. Growth hormone then reaches the liver, which produces insulin-like growth factor, called IGF-1, to help govern growth and repair [1].
Blood breaks the body's own message down fast. Enzymes in blood act like small scissors on that message [8]. Researchers altered four protein parts, so those scissors cut the drug less well. The change at spot 2 of the drug's chain did most to make it stronger and longer-lasting [7]. The DAC form adds a link to albumin, a protein found in your bloodstream [2]. That protein then carries the drug far longer.
For you, the point is that DAC stretches a minutes-long message across days.
What changed in the studies on people?
The main CJC-1295 study included healthy adults from age 21 to 61. They received one or more shots under the skin, each holding 30 or 60 micrograms per kilogram. Body weight set the total amount. With the smaller shot, average growth hormone reached 2 times its starting level; the larger shot raised it ten times. Both rises lasted six days or longer. Insulin-like growth factor, called IGF-1, stayed higher for 9 to 11 days. Your liver makes IGF-1 to help with growth and repair. After more doses, IGF-1 remained above its starting level through 28 days. Half the drug took about 5.8-8.1 days to leave [1]. Most claims about a long stay come from this small study.
Another study enrolled healthy men from age 20 to 40. They got one shot of 60 or 90 micrograms per kilogram. One week later, their daily growth-hormone average was about 46% higher. IGF-1 was about 45% higher, and their bodies kept releasing growth hormone in bursts of the same size and number [3]. Another test included 11 healthy young men. Several proteins carried in their blood changed after each dose. One protein change rose along with IGF-1 [5].
For you, the key limit is that these early studies don't show better health [1].
Did IGF-1 changes improve anyone's health?
No study showed that the hormone rise made a healthy person better. Larger study amounts led to larger blood-test rises. Growth hormone plus insulin-like growth factor, called IGF-1, stayed high for several days after a shot placed beneath the skin [1][3]. Those changes are the only CJC-1295 benefits shown in people. IGF-1 rose, but the studies don't prove better sleep, faster healing, or more strength.
The mouse work focused on growth. The mice couldn't make the body message needed for normal growth. Researchers gave them 2 micrograms every 24 hours. Their weight and length returned to normal, and their growth glands produced more growth hormone. The same amount every 48 to 72 hours worked less well [4]. You can apply that result only to those mice and amounts.
No large study tested a health benefit in healthy people. Human use remains unapproved [1]. A 2026 review found the same lack of proof for related research drugs used in bone or muscle care [14].
Your blood test can change without proving that your health improved.
Why did researchers pair CJC-1295 with ipamorelin?
Researchers paired the drugs because they start growth-hormone release in two ways. CJC-1295 copies the message sent toward the growth gland. Ipamorelin reaches a different receiving spot, which also responds to ghrelin, the hormone that can make you hungry [11]. Work in animals and cells suggests using both routes may release a larger hormone rise than either drug alone [11].
Ipamorelin was made to focus on growth-hormone release. In the cited work, other hormones tied to stress and milk-making changed very little [11]. In animals, the amount of ipamorelin in blood rose and fell with growth hormone [11]. Still, support for the pair comes mainly from animal work and how the drugs act. Tests in people haven't shown a clear health gain from CJC-1295 used with ipamorelin [11].
For you, the animal work gives no proof that the pair helps people.
What does “CJC-1295 with ipamorelin” mean?
The phrase means the two drugs were used together: CJC-1295 copies the body's order to release growth hormone, while ipamorelin starts release through another receiving spot [11]. Using both may raise the hormone more than using either one alone [11].
The pair is for research and has no approved product. Studies haven't shown a clear health gain from this exact pair in people [11], so the pairing idea doesn't prove either drug will help you.
Did the CJC-1295 drug pair help people feel better?
Studies have not found better health or healing from the pair. The two drugs can start growth-hormone release in different ways [11]. Work in animals and cells makes researchers want to test them together because the two routes add to each other [11].
For your question, no human test proves better health from this exact pair [11].
What long-term risks still have no answer?
Long-term CJC-1295 safety is still unknown. Growth hormone may tell your kidneys to hold salt and water. This may cause swelling. It can also make insulin less able to lower blood sugar [12]. Research across large groups links high IGF-1, the liver-made hormone tied to growth and repair, with slightly more cases of some cancers. That IGF-1 link doesn't show that CJC-1295 causes cancer. In 2024, FDA advisers also raised the chance of an immune attack on the drug.
No large, long CJC-1295 safety study has been done in people [1]. The first company, ConjuChem, stopped work on CJC-1295 with DAC. Its Phase 2 trial was a mid-stage test in people. It enrolled people with HIV who had fat around organs in the belly. The work did not move ahead [1]. A lab also detected the drug inside a seized bottle marked as a growth-hormone drug [6]. Read more about the reported concerns and unanswered risks.
No study can yet tell you the risk over months or years. That leaves you without a long-term answer.